文献速递艾滋病与性传播感染

法国暴露前预防实施首年:每日或按需使用替诺福韦/恩曲他滨

First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

法国药品管理局于2016年1月启动临时使用推荐,允许高危成人使用口服替诺福韦二吡呋酯/恩曲他滨进行HIV暴露前预防。本文报告实施首年数据:共3405人入组,2774份启动表完成,98.1%为男性,96.9%为男男性行为者,57%处方按需方案。研究期间报告4例突破性HIV感染,均发生于PrEP中断或启动时已处急性感染期。

要点

  • 法国PrEP首年使用者以MSM为主(96.9%),按需方案占57%。
  • 高龄(>50岁)和原IPERGAY研究点处方与按需方案使用相关。
  • 报告4例突破性HIV感染,均与PrEP中断或启动时急性感染有关。

核心结论

  • 在法国真实世界中,PrEP以每日或按需方案使用,主要人群为MSM,突破性感染罕见。

研究设计与样本

  • 法国药品管理局2016年1月启动临时使用推荐后,医生通过安全网络受试者监测界面收集启动表和HIV血清转换表数据。
  • 2016年1月4日至2017年2月28日共3405人入组,完成2774份启动表。
  • 采用单因素及多因素 logistic 回归分析基线因素与按需PrEP方案处方的关联。

主要发现

  • 98.1%为男性,96.9%为MSM,57%受试者被处方按需方案。
  • 年龄>50岁与按需处方相关(OR=1.76,95%CI 1.35-2.3,P<0.001)。
  • 原IPERGAY研究点处方与按需处方相关(OR=2.28,95%CI 1.84-2.83,P<0.001)。
  • 报告性传播感染(OR=0.68,95%CI 0.57-0.82)和无套肛交且至少两个不同伴侣(OR=0.75,95%CI 0.57-0.98)者更少接受按需PrEP(P<0.05)。
  • 研究期间报告4例突破性HIV感染,均发生于PrEP中断或启动时已处急性感染期。

关键数值与推荐

  • 法国药品管理局2016年1月启动临时使用推荐(TRU),允许高危成人口服替诺福韦二吡呋酯/恩曲他滨进行PrEP。
  • 按需方案处方占57%,每日方案占其余部分。
  • 年龄>50岁者接受按需处方的OR=1.76(95%CI 1.35-2.3,P<0.001)。
  • 原IPERGAY研究点处方按需方案的OR=2.28(95%CI 1.84-2.83,P<0.001)。

临床怎么用

  • 法国真实世界数据显示PrEP可按需或每日方案实施,MSM为主要使用人群。
  • 处方按需方案时需考虑年龄和处方点经验,高龄和原IPERGAY研究点更倾向按需方案。
  • 有STI或无套肛交多伴侣者更少接受按需方案,提示处方选择可能受风险特征影响。
  • 突破性感染虽罕见,但需关注PrEP中断和启动时急性感染筛查。

局限性

  • 数据基于医生填报的监测界面,可能存在报告偏倚。
  • 仅2774份启动表完成,3405人入组,数据完整性有限。
  • 未报告每日与按需方案的具体疗效比较。
  • 随访期间突破性感染仅4例,事件数少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In January 2016, the French Medicine Agency initiated a Temporary Recommendation for Use (TRU) to allow the use of oral intake of tenofovir disoproxil fumarate and emtricitabine for pre-exposure prophylaxis (PrEP) in adults at high risk of HIV. We report the results of the first year of PrEP implementation in France. METHODS: Data were collected by physicians using a secured web subject-monitoring interface, with two forms: an initiation form, with patients' baseline characteristics, and an HIV seroconversion form. Univariate and adjusted multivariate analysis using a logistic regression model were performed to identify baseline factors associated with on-demand PrEP regimen prescription. RESULTS: From 4 January 2016 to 28 February 2017, 3405 subjects were enrolled, with 2774 initiation forms completed; 98.1% were male and 96.9% were MSM. An on-demand regimen was prescribed to 57% of subjects. Older age (OR for participants older than 50 years = 1.76, 95% CI 1.35-2.3, P < 0.001) and site of prescription (OR of former IPERGAY sites = 2.28, 95% CI 1.84-2.83, P < 0.001) were associated with on-demand prescription. Those reporting sexually transmitted infection (STI) and condomless anal sex with at least two different partners were less likely to receive on-demand PrEP (OR = 0.68, 95% CI 0.57-0.82 and 0.75, 95% CI 0.57-0.98, respectively; P < 0.05 for all). Four breakthrough HIV infections were reported during the study, in the context of PrEP interruption or acute infection at the time of PrEP initiation. CONCLUSIONS: In a real-life setting in France, PrEP was used, either daily or on-demand, mostly by MSM, with breakthrough infections being rare.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Siguier M, Mera R, Pialoux G, et al. First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine. J Antimicrob Chemother. 2019. PMID: 31219561. doi:10.1093/jac/dkz220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。